Title (en)

PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR BETA-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Title (de)

ANALOGA UND MIMETIKA VON PEPTIDEN FÜR DIE IN-VIVO-VERWENDUNG IN DER BEHANDLUNG VON KRANKHEITEN, DIE MIT ABNORMALER PROTEINFALTUNG IN AMYLOID- ODER AMYLOID ÄHNLICHEN ABLAGERUNGEN ODER IHREM AN BETA-FALTBLATTSTRUKTUR REICHEM PATHOLOGISCHEM VORLÄUFER VERBUNDEN SIND

Title (fr)

ANALOGUES ET MIMETIQUES PEPTIDIQUES POUVANT ETRE UTILISES IN VIVO POUR TRAITER DES MALADIES ASSOCIEES AU REPLI ANORMAL PROTEIQUE EN DEPOTS AMYLOIDES OU PSEUDO-AMYLOIDES OU LEUR PRECURSEUR PATHOLOGIQUE RICHE EN BETA-FEUILLE

Publication

EP 1286590 A4 20050511 (EN)

Application

EP 00976928 A 20001104

Priority

• US 0030416 W 20001104
• US 16391199 P 19991105

Abstract (en)

[origin: WO0134631A2] The present invention is an inhibitory peptide capable of inhibiting beta pleated sheet formation in amyloid beta -peptide. The inhibitory peptide is a beta sheet breaker peptide analog designed by chemical modification of beta sheet breaker peptide capable of inhibiting beta pleated sheet formation in amyloid beta -peptide. The present invention also includes an inhibitory peptide capable of inhibiting conformational changes in prion PrP protein associated with amyloidosis. The inhibitory peptide being a beta sheet breaker peptide analog designed by chemical modification of a beta sheet breaker peptide capable of inhibiting the conformational changes in prior PrP protein associated with amyloidosis. In addition, the present invention includes a peptide mimetic with the structure PMiA beta 5. In another embodiment, the peptide mimetic has the structure PMiPrP13. In yet another embodiment, the peptide mimetic has the structure PMiPrP5.

[origin: WO0134631A2] The present invention is an inhibitory peptide capable of inhibiting beta pleated sheet formation in amyloid beta -peptide. The inhibitory peptide is a beta sheet breaker peptide analog designed by chemical modification of beta sheet breaker peptide capable of inhibiting beta pleated sheet formation in amyloid beta -peptide. The present invention also includes an inhibitory peptide capable of inhibiting conformational changes in prion PrP protein associated with amyloidosis. The inhibitory peptide being a beta sheet breaker peptide analog designed by chemical modification of a beta sheet breaker peptide capable of inhibiting the conformational changes in prior PrP protein associated with amyloidosis. In addition, the present invention includes a peptide mimetic with the structure PMiA beta 5. In another embodiment, the peptide mimetic has the structure PMiPrP13. In yet another embodiment, the peptide mimetic has the structure PMiPrP5.

IPC 1-7

A01N 37/18

IPC 8 full level

A61K 38/00 (2006.01); A61K 31/20 (2006.01); A61P 25/28 (2006.01); C07C 229/28 (2006.01); C07C 229/34 (2006.01); C07K 5/02 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 7/64 (2006.01); C07K 14/47 (2006.01)

CPC (source: EP KR)

A61P 25/28 (2017.12 - EP); C07C 229/34 (2013.01 - EP); C07K 5/0207 (2013.01 - EP); C07K 7/06 (2013.01 - KR); C07K 14/47 (2013.01 - EP); C07K 14/4711 (2013.01 - EP); A61K 38/00 (2013.01 - EP); C07C 2601/08 (2017.04 - EP)

Citation (search report)

• [Y] US 5854204 A 19981229 - FINDEIS MARK A [US], et al
• [X] PODUSLO J F ET AL: "BETA-SHEET BREAKER PEPTIDE INHIBITOR OF ALZHEIMER'S AMYLOIDOGENESIS WITH INCREASED BLOOD-BRAIN BARRIER PERMEABILITY AND RESISTANCE TO PROTEOLYTIC DEGRADATION IN PLASMA", JOURNAL OF NEUROBIOLOGY, JOHN WILEY AND SONS., NEW YORK, NY, US, vol. 39, no. 3, 5 June 1999 (1999-06-05), pages 371 - 382, XP009008758, ISSN: 0022-3034
• [YD] SOTO C: "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 77, no. 5, May 1999 (1999-05-01), pages 412 - 418, XP002203443, ISSN: 0946-2716
• [YD] SOTO C ET AL: "BETA-SHEET BREAKER PEPTIDES INHIBIT FIBRILLOGENESIS IN A RAT BRAIN MODEL OF AMYLOIDOSIS: IMPLICATIONS FOR ALZHEIMER'S THERAPY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 7, 1998, pages 822 - 826, XP000914747, ISSN: 1078-8956
• [Y] GANTE J: "PEPTIDOMIMETICS-TAILORED ENZYME INHIBITORS", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 33, no. 17, 16 September 1994 (1994-09-16), pages 1699 - 1720, XP000465275, ISSN: 0570-0833
• [YD] FAUCHERE J-L ET AL: "Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design", ADVANCES IN DRUG RESEARCH 1992 UNITED KINGDOM, vol. 23, 1992, pages 127 - 159, XP009036334, ISSN: 0065-2490
• See references of WO 0134631A2

Citation (examination)

• ADESSI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2003, pages 13905 - 13911
• ROSSI ET AL., BIOPOLYMERS, vol. 40, 1996, pages 465 - 478, XP009074244
• BASU ET AL, BIOPOLYMERS, vol. 31, 1991, pages 1763 - 1774, XP002056915
• ALI ET AL., ACTA CHIMICA SCANDICANICA, vol. 27, 1973, pages 1509 - 1518
• TONIOLO ET AL., PEPTIDE RESEARCH, vol. 5, 1992, pages 56 - 61

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0134631 A2 20010517; WO 0134631 A3 20021227; AU 1463501 A 20010606; AU 781044 B2 20050505; BR 0015513 A 20040706; CA 2389041 A1 20010517; CN 1437442 A 20030820; EA 004739 B1 20040826; EA 200200536 A1 20021226; EP 1286590 A2 20030305; EP 1286590 A4 20050511; IL 149392 A0 20021110; JP 2004513873 A 20040513; KR 20020079731 A 20021019; KR 20060133114 A 20061222; MX PA02004468 A 20040910

DOCDB simple family (application)

US 0030416 W 20001104; AU 1463501 A 20001104; BR 0015513 A 20001104; CA 2389041 A 20001104; CN 00819247 A 20001104; EA 200200536 A 20001104; EP 00976928 A 20001104; IL 14939200 A 20001104; JP 2001537342 A 20001104; KR 20027005797 A 20020504; KR 20067025305 A 20061130; MX PA02004468 A 20001104